黄斑变性
医学
糖尿病性视网膜病变
血管内皮生长因子
病态的
脉络膜新生血管
失明
视网膜
新生血管
血管抑制剂
视网膜分支静脉阻塞
贝伐单抗
血管生成
眼科
视网膜静脉
药品
糖尿病
人口
视网膜
黄斑水肿
血管内皮生长因子受体
外科
药理学
病理
内科学
神经科学
验光服务
化疗
内分泌学
生物
环境卫生
作者
Shinsuke Nakamura,Hideaki Hara
出处
期刊:Journal of the Pharmaceutical Society of Japan
日期:2021-11-30
卷期号:141 (12): 1307-1317
被引量:1
标识
DOI:10.1248/yakushi.21-00158-1
摘要
The number of patients with exudative age-related macular degeneration, diabetic retinopathy and retinal vein occlusion is expected to rise in proportion with the aging of the population and increasing diabetes patients. Also, they are the most common diseases caused by intraocular neovascularization and are often difficult to treat. Currently, anti-vascular endothelial growth factor (VEGF) therapy has been developed and has demonstrated excellent results in treating macular edema, and many patients have avoided blindness. Unfortunately, there are problems with cases that do not respond to the anti-VEGF drugs and complications of administration. It is necessary to deepen the understanding of the physiological and pathological retinal roles of VEGF and to optimize the anti-VEGF therapy. There are also no drugs indicated for the regression of neovascularization itself. The solution to this problem is to develop novel therapies targeting other than VEGF. In this symposium review, we introduce the roles of VEGF in the ischemic retina and anti-angiogenic factors as promising therapeutic targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI